{
  "model": "gpt-5.1-codex-mini",
  "agentReasoning": "medium",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 1,
  "workspacePath": "workspaces/gpt-5-1-codex-mini-tumor-vaccine-ici-run-1",
  "success": false,
  "schemaPass": false,
  "toolTracePass": true,
  "graderPass": true,
  "durationMs": 133986,
  "agentCostUsd": 0.0306442,
  "graderCostUsd": 0.008182499999999999,
  "totalCostUsd": 0.0388267,
  "agentUsage": {
    "promptTokens": 88780,
    "cachedTokens": 78848,
    "responseTokens": 3431,
    "thinkingTokens": 9664,
    "totalTokens": 101875
  },
  "graderUsage": {
    "promptTokens": 3930,
    "cachedTokens": 0,
    "responseTokens": 208,
    "thinkingTokens": 3392,
    "totalTokens": 7530
  },
  "totalUsage": {
    "promptTokens": 92710,
    "cachedTokens": 78848,
    "responseTokens": 3639,
    "thinkingTokens": 13056,
    "totalTokens": 109405
  },
  "modelVersions": [
    "gpt-5.1-codex-mini"
  ],
  "agentFinalText": "Completion checklist:\n- [x] output/study_overview.json\n- [x] output/quantitative_findings.json\n- [x] output/claim_audit.json\n- [x] output/public_summary.json",
  "outputValidation": [
    {
      "outputFile": "output/study_overview.json",
      "schemaFile": "schemas/study_overview.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Can intratumoral SARS-CoV-2 mRNA vaccination broaden antigen presentation and interferon signaling to sensitize tumors to anti-PD-L1 therapy?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-combo\",\n      \"label\": \"Mouse combination therapy cohort\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice pooled across repeat experiments\",\n      \"description\": \"Intratumoral mRNA vaccine plus anti-PD-L1 was evaluated across multiple murine tumor models to test whether tumors could be sensitized to checkpoint blockade.\"\n    },\n    {\n      \"id\": \"mouse-controls\",\n      \"label\": \"Mouse matched control cohorts\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice pooled across matched controls\",\n      \"description\": \"Matched vaccine-only, ICI-only, and vehicle-treated cohorts were maintained to benchmark the combination effects in murine models.\"\n    },\n    {\n      \"id\": \"human-retrospective\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 metastatic patients\",\n      \"description\": \"Retrospective analysis compared prior SARS-CoV-2 mRNA vaccinated (43) and unvaccinated (87) metastatic patients receiving ICI to probe clinical correlates.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized, so residual confounding is likely present.\",\n    \"Vaccination timing relative to ICI initiation varied across patients, limiting temporal clarity.\",\n    \"Tumor-type mix and treatment-history heterogeneity make it hard to interpret group differences causally.\",\n    \"Mouse model effects may not map one-to-one to all human tumors tested clinically.\"\n  ]\n}"
    },
    {
      "outputFile": "output/quantitative_findings.json",
      "schemaFile": "schemas/quantitative_findings.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3% in vaccine/combination arm\",\n      \"comparator_or_baseline\": \"37.3% without vaccination\",\n      \"interpretation\": \"Broader antigen display was achieved after intratumoral mRNA vaccination.\",\n      \"evidence_line_refs\": [\n        \"L28\"\n      ]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6% in vaccinated tumors\",\n      \"comparator_or_baseline\": \"20.6% baseline\",\n      \"interpretation\": \"The MHC-I-presented landscape expanded strongly after mRNA vaccination.\",\n      \"evidence_line_refs\": [\n        \"L29\"\n      ]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01 for vaccinated subgroup\",\n      \"comparator_or_baseline\": \"Unvaccinated subgroup under ICI\",\n      \"interpretation\": \"Vaccinated patients had improved survival while receiving ICI treatment.\",\n      \"evidence_line_refs\": [\n        \"L30\"\n      ]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1 after vaccination\",\n      \"comparator_or_baseline\": \"1.0 prior\",\n      \"interpretation\": \"Type I interferon signaling was markedly induced by the mRNA vaccine.\",\n      \"evidence_line_refs\": [\n        \"L31\"\n      ]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x with combination therapy\",\n      \"comparator_or_baseline\": \"1.0x baseline\",\n      \"interpretation\": \"The checkpoint axis became more targetable after the vaccine plus anti-PD-L1 intervention.\",\n      \"evidence_line_refs\": [\n        \"L32\"\n      ]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x with combination therapy\",\n      \"comparator_or_baseline\": \"1.0x baseline\",\n      \"interpretation\": \"Combination therapy increased immune infiltration in tumors.\",\n      \"evidence_line_refs\": [\n        \"L33\"\n      ]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/claim_audit.json",
      "schemaFile": "schemas/claim_audit.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": false,
      "errors": [
        "Quote in C03 was not found verbatim in report: \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment.\""
      ],
      "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination broadens interferon signaling and antigen processing to sensitize tumors.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        },\n        {\n          \"quote\": \"Interferon-associated antigen processing and presentation pathways increase.\",\n          \"line_ref\": \"L43\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"Combining the mRNA vaccine with anti-PD-L1 therapy improves tumor control in mice and mirrors better retrospective human outcomes.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\n          \"line_ref\": \"L45\"\n        },\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        }\n      ],\n      \"caveat\": \"Human survival data come from a retrospective, non-randomized cohort subject to confounding and heterogeneity.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"Prior SARS-CoV-2 mRNA vaccination was associated with improved survival among metastatic patients receiving ICI.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\",\n          \"line_ref\": \"L15\"\n        },\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment.\",\n          \"line_ref\": \"L30\"\n        }\n      ],\n      \"caveat\": \"Retrospective design, variable vaccination timing, and patient heterogeneity limit causal interpretation of the human survival association.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Mechanistic probes including IFNAR1 blockade showed the sensitization benefit depends on type I interferon signaling.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).\",\n          \"line_ref\": \"L16\"\n        },\n        {\n          \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        }\n      ],\n      \"caveat\": \"Mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/public_summary.json",
      "schemaFile": "schemas/public_summary.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"headline\": \"SARS-CoV-2 mRNA vaccination primes tumors for PD-L1 blockade in mice and human cohorts\",\n  \"plain_language_summary\": \"Researchers tested whether injecting SARS-CoV-2 mRNA vaccine directly into tumors could create an inflammatory state that makes anti-PD-L1 therapies more effective. In mice the vaccine broadened the immunopeptidome and MHC-I landscape, raised PD-L1 and CD8+ density, and improved combination efficacy while vaccine-only or ICI-only arms failed to control non-immunogenic tumors, lipid particle controls lacking mRNA did not reproduce the effect, and blocking IFNAR1 eliminated the sensitization benefit. A retrospective cohort of 43 vaccinated versus 87 unvaccinated metastatic patients on ICI also showed better survival for vaccinated individuals, although the human data remain observational and heterogeneous.\",\n  \"what_is_new\": [\n    \"Intratumoral SARS-CoV-2 mRNA vaccination broadened tumor antigen display and MHC-I presentation in murine models.\",\n    \"The vaccine plus anti-PD-L1 combination raised PD-L1 expression and CD8+ T cell density, supporting stronger murine tumor control.\",\n    \"Vaccinated metastatic patients on ICI showed statistically better survival than unvaccinated peers in the retrospective cohort.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human analysis is retrospective and non-randomized, so residual confounding is likely present.\",\n    \"Vaccination timing relative to ICI initiation varied across patients, limiting temporal clarity.\",\n    \"Tumor-type mix and treatment-history heterogeneity make it hard to interpret group differences causally.\",\n    \"Mouse model effects may not map one-to-one to all human tumors tested clinically.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A vaccine that delivers messenger RNA encoding an antigen so that cells produce the target protein and stimulate immune responses; here, SARS-CoV-2 mRNA vaccine was injected into tumors.\"\n    },\n    {\n      \"term\": \"Immune checkpoint blockade\",\n      \"definition\": \"Therapies such as anti-PD-L1 antibodies that block inhibitory signals on T cells, enabling them to attack cancer cells more effectively.\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"The repertoire of peptides presented by MHC molecules on tumor cells, which determines what T cells can recognize.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"A family of cytokines that activates antiviral states and enhances antigen processing, which was linked to tumor sensitization in this study.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Will randomized trials confirm that intratumoral mRNA vaccination improves checkpoint blockade responses in humans?\",\n    \"Can the interferon-driven expansion of the immunopeptidome be reproduced across tumor types with different baseline immunogenicity?\",\n    \"How durable are responses when patients receive intratumoral mRNA vaccines plus checkpoint inhibitors?\"\n  ]\n}"
    }
  ],
  "toolTrace": {
    "pass": true,
    "totalCalls": 24,
    "failedCalls": 0,
    "toolsUsed": [
      "list_directory",
      "read_file",
      "write_file"
    ],
    "hasSuccessfulRead": true,
    "hasSuccessfulWrite": true,
    "pathPolicyViolations": [],
    "notes": [],
    "calls": [
      {
        "source": "llm",
        "step": 1,
        "toolName": "list_directory"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "list_directory"
      },
      {
        "source": "llm",
        "step": 5,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 6,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 7,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 8,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 9,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 10,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 11,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 12,
        "toolName": "write_file"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": ".",
        "timestamp": "2026-02-24T00:18:53.842Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "TASK.md",
        "timestamp": "2026-02-24T00:18:55.110Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "input/report.md",
        "timestamp": "2026-02-24T00:18:56.611Z"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": "schemas",
        "timestamp": "2026-02-24T00:18:58.280Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/study_overview.schema.json",
        "timestamp": "2026-02-24T00:18:59.478Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/quantitative_findings.schema.json",
        "timestamp": "2026-02-24T00:19:01.171Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/claim_audit.schema.json",
        "timestamp": "2026-02-24T00:19:02.871Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/public_summary.schema.json",
        "timestamp": "2026-02-24T00:19:04.353Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/study_overview.json",
        "timestamp": "2026-02-24T00:20:04.467Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-24T00:20:12.241Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-24T00:20:22.853Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/public_summary.json",
        "timestamp": "2026-02-24T00:20:38.993Z"
      }
    ]
  },
  "grader": {
    "model": "chatgpt-gpt-5.1-codex-mini",
    "value": {
      "verdict": "pass",
      "scores": {
        "faithfulness": 5,
        "coverage": 4,
        "usefulness": 5
      },
      "critical_issues": [
        "Claim audit JSON fails grounding validation because the quoted table row for the retrospective survival comparison (L30) is not captured verbatim; the reference should be reformatted so automated checks can confirm the grounding."
      ],
      "summary": "The three JSON outputs largely reflect the report’s quantitative metrics (L25‑34) and limitations (L48‑54) and thus remain useful for downstream review. Study overview and public summary accurately describe the mouse and human cohorts, interferon-driven mechanism, and caveats such as the retrospective human data. Quantitative findings align with the reported antigen‑presentation, interferon and PD-L1/CD8+ changes, and controls (L36‑39), though the claim audit needs its quoted string for the p=0."
    }
  }
}
